154 related articles for article (PubMed ID: 15217948)
1. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.
Li R; Heydon K; Hammond ME; Grignon DJ; Roach M; Wolkov HB; Sandler HM; Shipley WU; Pollack A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4118-24. PubMed ID: 15217948
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
[TBL] [Abstract][Full Text] [Related]
3. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
4. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
5. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10.
Chakravarti A; Heydon K; Wu CL; Hammond E; Pollack A; Roach M; Wolkov H; Okunieff P; Cox J; Fontanesi J; Abrams R; Pilepich M; Shipley W;
J Clin Oncol; 2003 Sep; 21(17):3328-34. PubMed ID: 12947069
[TBL] [Abstract][Full Text] [Related]
6. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
7. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
[TBL] [Abstract][Full Text] [Related]
9. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
10. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation.
Spalding AC; Daignault S; Sandler HM; Shah RB; Pan CC; Ray ME
Urology; 2007 May; 69(5):936-40. PubMed ID: 17482938
[TBL] [Abstract][Full Text] [Related]
11. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; MartÃnez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
12. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
13. Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10.
Torres-Roca JF; DeSilvio M; Mora LB; Khor LY; Hammond E; Ahmad N; Jove R; Forman J; Lee RJ; Sandler H; Pollack A
Urology; 2007 Mar; 69(3):505-9. PubMed ID: 17382154
[TBL] [Abstract][Full Text] [Related]
14. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
15. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
16. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
Andrews SF; Horwitz EM; Feigenberg SJ; Eisenberg DF; Hanlon AL; Uzzo RG; Pollack A
Cancer; 2005 Jul; 104(2):299-304. PubMed ID: 15954083
[TBL] [Abstract][Full Text] [Related]
17. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
18. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
Cheng L; Pisansky TM; Sebo TJ; Leibovich BC; Ramnani DM; Weaver AL; Scherer BG; Blute ML; Zincke H; Bostwick DG
Clin Cancer Res; 1999 Oct; 5(10):2820-3. PubMed ID: 10537347
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
20. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
